Common Sense Oncology shared a post on LinkedIn:
“Just published in The Lancet Oncology, a commentary by CSO members.
Drs. Sam Stevens, Laure-Anne Teuwen, and mentor Bishal Gyawali commends and provides further recommendations to the FDA’s latest guidance on randomized cancer drug trials.”
Title: Overall survival assessment in cancer drug trials: a luxury or a necessity?
Authors: Samuel X. Stevens, Laure-Anne Teuwen, Bishal Gyawali
Read the full article on The Lancet Oncology.
More posts featuring Common Sense Oncology on OncoDaily.
